Edward Collins
Newgen Software Wins $8.8M ECM Contract – Analysis
Newgen Software Technologies’ Contract Secured – Analyzed Newgen Software Technologies, a global company specializing in software solutions, has won a big deal. They’ve been chosen....
Ashoka Buildcon Stock Drop: NHAI Investigation & Key Points
Ashoka Buildcon’s Performance Analyzed Ashoka Buildcon’s stock price dropped significantly after the National Highways Authority of India (NHAI) temporarily stopped the company from bidding on....
BSE Stock Gains: Allcargo, Refex, and More
Stock Market Gains: An Analysis of Key Performers Today, November 28, 2025, several stocks within the ‘A’ group on the BSE (Bombay Stock Exchange) experienced....
Nifty 50 Index Analysis: Performance & Sector Trends
Nifty 50 Index Performance Analyzed The Nifty 50 index, a key measure of India’s stock market, recently reached a new high for the year 2025.....
Belrise Industries Analysis: Buy Rating & Growth Forecast
Belrise Industries Analyzed Key Points JM Financial rates Belrise Industries ‘Buy’ with a ₹215 target. Belrise is a top 3 player in India’s 2W metal....
Refex Industries Share Price Analysis – November 2025
Refex Industries Share Price Analyzed Refex Industries saw a strong rise in its share price on November 28, 2025. The stock jumped by 13.5% to....
VST Tillers Share Price Analysis – November 2025
VST Tillers Tractors Share Price Analyzed On November 28, 2025, VST Tillers Tractors saw a significant jump in its share price, rising by 5.43% to....
Sudeep Pharma Share Price Analysis: Debut Performance
Sudeep Pharma Share Price Analyzed Sudeep Pharma, which makes special ingredients for medicines, started trading on the stock market (called the NSE and BSE) after....
Mahindra & Mahindra Stock: Nomura’s Buy Rating
Nomura Analyzed: Mahindra & Mahindra Stock Nomura, a large investment firm, strongly believes that Mahindra & Mahindra (M&M) is a good investment. They’ve given the....
Anthem Biosciences: Nomura’s Buy Rating & ₹740 Target
Anthem Biosciences: Analysis by Nomura Nomura has started following Anthem Biosciences, giving it a “Buy” rating and predicting the stock will rise to ₹740. This....
